Triaminotriazine DNA helicase inhibitors with antibacterial activity

Bioorganic and Medicinal Chemistry Letters

Volumn 16, Issue 5, 2006, Pages 1286-1290

  McKay, Geoffrey A ^a   Reddy, Ranga ^a   Arhin, Francis ^a   Belley, Adam ^a   Lehoux, Dario ^a   Moeck, Greg ^a   Sarmiento, Ingrid ^a   Parr, Thomas R ^a   Gros, Philippe ^b   Pelletier, Jerry ^b   Far, Adel Rafai ^a  

^a Targanta Therapeutics Inc   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Antibacterial; Cytotoxic; Helicase

Indexed keywords

ANTIINFECTIVE AGENT; DISTAMYCIN A; DNA B; HELICASE; RNA; TRIAMINOTRIAZINE INHIBITOR; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ARTICLE; CYTOTOXICITY; DNA REPLICATION; DRUG ACTIVITY; DRUG IDENTIFICATION; DRUG MECHANISM; DRUG SCREENING; ENZYME ACTIVITY; ENZYME INHIBITION; HELA CELL; HUMAN; HUMAN CELL; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS; STRUCTURE ACTIVITY RELATION;

MAMMALIA; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS;

EID: 31344461673     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2005.11.076     Document Type: Article

References (31)

1. K.M. Overbye, and J.F. Barrett Drug Discovery Today 10 2005 45
2. S.B. Levy Adv. Drug Delivery Rev. 57 2005 1446
3. M.T. Black, and J. Hodgson Adv. Drug Delivery Rev. 57 2005 1528
4. E.D. Brown, and G.D. Wright Chem. Rev. 105 2005 759
5. E.H. Egelman J. Struct. Biol. 124 1998 123
6. N. Tuteja, and R. Tuteja Eur. J. Biochem. 271 2004 1835
7. J.M. Caruthers, and D.B. McKay Curr. Opin. Struct. Biol. 12 2002 123
8. For an example of the essentiality of the helicase in S. aureus: J. Liu, M. Dehbi, G. Moeck, F. Arhin, P. Bauda, D. Bergeron, M. Callejo, V. Ferretti, N. Ha, T. Kwan, J. McCarthy, R. Srikumar, D. Williams, J.J. Wu, P. Gros, J. Pelletier, and M. DuBow Nat. Biotechnol. 22 2004 185
9. A. Van Der Ende, T.A. Baker, T. Ogawa, and A. Kornberg Proc. Natl. Acad. Sci. U.S.A. 82 1985 3954
10. M.J. Davey, and M. O'Donnell Curr. Biol. 13 2003 R594
11. P. Houston, and T. Kodadek Proc. Natl. Acad. Sci. U.S.A. 91 1994 5471
12. R.K. Soni, P. Mehra, N.R. Choudhury, G. Mukhopadhyay, and S.K. Dhar Nucleic Acids Res. 31 2003 6828
13. Z. Zhong, D. Helinski, and A. Toukdarian J. Biol. Chem. 278 2003 45305
14. R. Caspi, M. Pacek, G. Consiglieri, D.R. Helinski, A. Toukdarian, and I. Konieczny EMBO J. 20 2001 3262
15. M. Trautmann, P.M. Lepper, and M. Haller Am. J. Infect. Control 33 2005 S41
16. J.B. Goldberg, and G.B. Pier Trends Microbiol. 8 2000 514
17. Y. Zhang, F. Yang, Y.-C. Kao, M.G. Kurilla, D.L. Pompliano, and I.B. Dicker Anal. Biochem. 304 2002 174
18. G. Malich, B. Markovic, and C. Winder Toxicology 124 1997 179
19. J.W. George, S. Ghate, S.W. Matson, and J.M. Besterman J. Biol. Chem. 261 1992 10683
20. D.L. Boger, B.E. Fink, S.R. Brunette, W.C. Tse, and M.P. Hedrick J. Am. Chem. Soc. 123 2001 5878
21. D.L. Boger, B.E. Fink, and M.P. Hedrick J. Am. Chem. Soc. 122 2000 6382
22. National Committee for Clinical Laboratory Standards: Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically, 4th ed.: Approved Standard M7-A4. Wayne (PA): NCCLS.
23. Calculated with Pallas PrologD, CompuDrug International, Inc.; Sedona, AZ, USA, 2003.
24. The negative impact of higher log P values on antibacterials has already been noted. See: M.T.D. Cronin, A.O. Aptula, J.C. Dearden, J.C. Duffy, T.I. Netzeva, H. Patel, P.H. Rowe, T.W. Schultz, A.P. Worth, K. Voutzoulidis, and G. Schüürmann J. Chem. Inf. Comput. Sci. 42 2002 869
25. C. Kaito, K. Kurokawa, M.S. Hossain, N. Akimitsu, and K. Sekimizu FEMS Microbiol. Lett. 210 2002 157
26. Although a number of inhibitors of mammalian and viral helicases exist, the only report of inhibitors of bacterial helicases is: H. Xu, G. Zieglin, W. Schröder, J. Frank, S. Ayora, J.C. Alonso, E. Lanka, and W. Saenger Nucleic Acids Res. 29 2001 5058
27. J.J. Hilliard, R.M. Goldschmidt, L. Licata, E.Z. Baum, and K. Bush Antimicrob. Agents Chemother. 43 1999 1693
28. M.D. Brazas, and R.E.W. Hancock Drug Discovery Today 10 2005 1245
29. For the use of serum to detect promiscuity in antibacterial assays: S. Roychoudhury, J.L. Brill, W.-P. Lu, R.E. White, Z. Chen, and T.P. Demuth Jr. J. Biomol. Screening 8 2003 555
30. For the use of serum albumin to detect promiscuity in in vitro enzymatic assays: S.L. McGovern, E. Caselli, N. Grigorieff, and B.K. Shoichet J. Med. Chem. 45 2002 1712
31. J. Gisby, and J. Bryant Antimicrob. Agents Chemother. 44 2000 255